Alexander P, Powles R
Clin Haematol. 1978 Jun;7(2):275-94. doi: 10.1016/s0308-2261(78)80006-x.
Conclusions are difficult to draw. In the six studies of immunotherapy of AML discussed, all the three employing BCG and cells showed a prolongation of survival and the major contributing factor to this prolongation of survival was extension of life after relapse. In the three studies using BCG alone only one shows a beneficial effect, but some more time must be allowed to elapse before this can be concluded with confidence.
很难得出结论。在所讨论的六项关于急性髓性白血病免疫疗法的研究中,所有三项使用卡介苗和细胞的研究都显示生存期延长,而生存期延长的主要促成因素是复发后生命的延长。在三项仅使用卡介苗的研究中,只有一项显示出有益效果,但在有把握地得出结论之前,还需要更多时间。